New research suggests that individuals who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who halt conventional diet and exercise regimens.
Research printed in a major health publication demonstrates that while obese individuals can lose substantial amounts of their body weight while using the jabs, the weight comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Individuals buying these medications should be informed of the risk of fast rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to starting weight in about one and a half years.
Weighing Therapies
The research, which reviewed 37 of trials involving thousands of participants, contrasted the results of GLP-1 agonists with conventional dieting.
Scientists note that people who lose weight through lifestyle changes alone typically experience a more gradual weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Experts believe the way of the drugs is key to understanding the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
Medical guidelines advise the injections for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
A number of clinicians argue that, due to the high risk of relapse, the therapy is often long-term.
This opinion is reinforced by drug manufacturers, who note that the results "highlight the chronic character of obesity," comparing it to managing conditions like diabetes.
User Experiences
Individuals who have discontinued the medication explain a powerful return of cravings.
"It felt as if something flipping and you're instantly starving," described a patient.
This difficulty is worsened if individuals have not established permanent dietary or behavioural changes during therapy.
Widespread Interest
Figures indicate that millions of people in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is more common among women than males.
- The middle-aged demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while the jabs are potent agents for weight loss, they are not a standalone cure and maintained weight loss likely depends on ongoing lifestyle support.
